Browse News
Filter News
Found 25 articles
-
Marengo Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial of its Novel TCR Vβ Directed Antibody-Fusion Molecule STAR0602, in Cancer Patients Refractory to Anti-PD1 Therapy
1/27/2023
Marengo Therapeutics, Inc., a company pioneering novel therapeutics targeting the T cell receptor (TCR) Vβ to selectively activate the right T cell subsets to fight cancer, today announced that the first patient has been dosed in its ongoing clinical trial of STAR0602 (START-001).
-
Marengo Therapeutics Presents Preclinical Data Supporting Clinical Investigation of its Lead Asset, STAR0602, at the 2022 Society for Immunotherapy of Cancer (SITC) Annual Meeting
11/10/2022
Marengo Therapeutics, Inc., a company pioneering novel therapeutics targeting the T cell receptor Vβ chain (TCR Vβ) to selectively activate the right T cell subsets to fight cancer, today will be presenting preclinical data that characterizes the mechanism of action and confirms robust anti-tumor activity for its novel T cell-activating antibody STAR0602 at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting in Boston.
-
Marengo Therapeutics Presents Preclinical Proof-of Concept Data for STAR0602, a First-in-class Selective T cell Activator, at the 34th EORTC-NCI-AACR Symposium 2022
10/28/2022
Marengo Therapeutics, Inc. presented the first preclinical proof-of-concept data on STAR0602, its novel TCR agonist antibody, during the 34th EORTC-NCI-AACR Symposium on molecular targets and cancer therapeutics in Barcelona, Spain.
-
Ipsen Delivers Strong Sales Growth in the First Nine Months of 2022 and Confirms Its Full-year Guidance
10/27/2022
Ipsen, a global specialty-driven biopharmaceutical company, presents its sales performance for the year to date and the third quarter of 2022.
-
The past week saw promising developments in candidate therapies for cancer, congenital hyperinsulinism, chronic cough and COVID-19 vaccines.
-
Marengo Therapeutics Advances First-In-Class Selective T cell Activator, STAR0602, into Human Trials in Solid Tumors and Enters Cooperative Research and Development Agreement with the National Cancer Institute
9/16/2022
Marengo Therapeutics today announced it is advancing its lead TCR activator, STAR0602, into the clinic following clearance of its investigational new drug (IND) application by the FDA.
-
Ipsen said that Onivyde did not show greater benefit than topotecan used in patients with SCLC who have progressed on or after platinum-based first-line therapy treatment.
-
Marengo Therapeutics and Ipsen have entered into a strategic, multi-year partnership to usher two of Marengo’s precision T cell immuno-oncology candidates into the clinic.
-
Ipsen and Marengo Therapeutics Announce Strategic Partnership to Advance Two Precision Immuno-Oncology Candidates From Marengo’s STAR Platform Into the Clinic
8/1/2022
Ipsen and Marengo Therapeutics, Inc. announced a strategic partnership to advance two of Marengo’s preclinical STAR platform-generated candidates into the clinic.
-
Marengo Therapeutics Announces Formation of Scientific Advisory Board to Advance the Company's Development of Novel Therapeutics for Precision Immuno-Oncology
7/12/2022
Marengo Therapeutics, Inc today announced the formation of its Scientific Advisory Board (SAB).
-
This week's Movers & Shakers includes a number of chief business officers and business development leaders alongside those tapped for scientific roles.
-
Marengo Therapeutics Expands Executive Leadership Team with Svetlana Makhni Joining as Chief Financial Officer
6/15/2022
Marengo Therapeutics, Inc., a company pioneering novel therapeutics that directly target the Vβ chain of the T cell receptor (TCR) to activate the right T cell subsets to fight cancer, today announced the appointment of Svetlana Makhni as Chief Financial Officer, further bolstering Marengo's C-suite leadership credentials.
-
Life sciences and biopharma companies strengthen their leadership teams and boards with these Movers & Shakers.
-
Marengo Therapeutics Appoints Ke Liu, MD, PhD, and Bruce Chabner, MD, to Key Leadership Roles, Strengthening Marengo's Development Team and Supporting Translation to the Clinic
5/9/2022
Marengo Therapeutics, Inc. today announced the appointment of Ke Liu, M.D., Ph.D., as Chief Development Officer, as well as Bruce Chabner, M.D., as Senior Strategic Advisor.
-
Marengo Therapeutics to Participate in Investor, Scientific, Industry Conferences
3/9/2022
Marengo Therapeutics, Inc., a company pioneering novel therapeutics that selectively activate T cells via the T cell receptor Vβ chain to combat cancer, announced that it will participate in the following investor, scientific, and industry conferences.
-
Marengo Therapeutics to Present at Annual J.P. Morgan Health Care Conference
1/6/2022
Marengo Therapeutics, Inc. today announced that Zhen Su , M.D., MBA, Chief Executive Officer of Marengo Therapeutics, will present at the 40th Annual J.P. Morgan Health Care Conference.
-
Money on the Move: November 3 – 9
11/10/2021
Investors are lighting up the season already for these biotechs, now flush with cash to spend. Here's who snagged funding this week. -
The $80 million infusions from ATP will advance Marengo’s lead candidate, STAR0602, which aims to treat advanced and metastatic solid tumors.
-
Marengo Therapeutics Launches with $80M from ATP, Appoints CEO Zhen Su, MD, to Deliver Breakthrough Cancer Treatments Using Its Selective T Cell Activation Repertoire (STAR) Platform
11/8/2021
ATP, a leader in life sciences venture capital, today announced the launch of Marengo Therapeutics, Inc.
-
Immunitas Therapeutics Appoints Seng-Lai 'Thomas' Tan, Ph.D. as Chief Scientific Officer
9/8/2021
Immunitas Therapeutics ("Immunitas"), a single cell genomics-based therapeutics company, has appointed Seng-Lai "Thomas" Tan, Ph.D., as Chief Scientific Officer.